We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Simple Blood Test Quickly and Accurately Diagnoses Potentially Life-Threatening Inflammatory Disease

By LabMedica International staff writers
Posted on 23 Feb 2024

Sarcoidosis, a chronic inflammatory condition characterized by small lumps known as granulomas in the lungs and other organs, remains a medical mystery with its exact cause yet to be understood. More...

Current theories suggest it might be an immune disorder triggered by specific antigens, usually foreign substances that provoke an immune response. Diagnosing sarcoidosis is currently a complex process that typically involves tissue removal and testing, accompanied by additional screenings to exclude other conditions like tuberculosis or lung cancer. Now, researchers have developed a tool that uses a simple blood test to rapidly and inexpensively diagnose sarcoidosis, potentially reducing the need for more invasive diagnostic techniques presently used to detect the disease.

In a research project supported by the National Institutes of Health (NIH, Bethesda, MD, USA), researchers at Wayne State University (Detroit, MI, USA) set out to identify antigens and determine which might be linked to sarcoidosis. They collected lung fluid and blood cell samples from patients with pulmonary sarcoidosis and extracted genetic material from these samples. Through a series of molecular techniques, the team successfully identified two novel antigen biomarkers specific to sarcoidosis, which bind only to antibodies found in sarcoidosis-positive patients.

Subsequently, the team developed a highly specific blood test that requires only a small blood sample to detect sarcoidosis accurately. To evaluate the effectiveness of their test, the researchers analyzed blood samples from a diverse group of 386 individuals, including patients diagnosed with sarcoidosis, tuberculosis, lung cancer, and healthy controls. Their findings confirmed that the test could effectively distinguish individuals with sarcoidosis from those with other respiratory diseases, marking a significant advancement in the diagnosis of sarcoidosis.

“Currently, diagnosing sarcoidosis isn’t a straightforward process, and requires tissue removal and testing with additional screenings to rule out other diseases, such as tuberculosis or lung cancer,” said James Kiley, Ph.D., Director of the Division of Lung Diseases at the National Heart, Lung, and Blood Institute, part of NIH. “Using a blood test will help diagnose faster, particularly in those organs that are more challenging to biopsy and with less harm to the patient.”

Related Links:
NIH
Wayne State University


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.